Estimating preventable fractions of disease caused by a specified biological mechanism: PAHs in smoking lung cancers as an example

Risk Analysis

Volumn 26, Issue 4, 2006, Pages 881-892

  Cox Jr , Louis Anthony ^a   Sanders, Edward ^b  

^a Cox Associates ^*  (United States)

^b Philip Morris   (Switzerland)

Author keywords

Causality; Lung cancer; PAH; Population attributable fraction; Preventable fraction

Indexed keywords

BIOMECHANICS; EPIDEMIOLOGY; PULMONARY DISEASES; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL METHODS; TUMORS;

CAUSALITY; LUNG CANCER; POLYCYCLIC AROMATIC HYDROCARBON (PAH); POPULATION ATTRIBUTABLE FRACTION; PREVENTABLE FRACTION;

DISEASE CONTROL;

BENZO(A)PYRENE DIOL EPOXIDE DNA; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; UNCLASSIFIED DRUG;

CANCER; DISEASE INCIDENCE; EPIDEMIOLOGY; ESTIMATION METHOD; HEALTH RISK; PAH; REGRESSION ANALYSIS; RISK ASSESSMENT; SMOKING;

ATTRIBUTABLE RISK; CANCER PREVENTION; CANCER RISK; CAUSAL ATTRIBUTION; CIGARETTE SMOKING; HUMAN; LUNG ALVEOLUS CELL; LUNG CANCER; PREVENTION STUDY; PRODUCT DEVELOPMENT; REVIEW; RISK ASSESSMENT; TOBACCO;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; DNA ADDUCTS; GENES, P53; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MUTATION; POLYCYCLIC HYDROCARBONS, AROMATIC; RISK ASSESSMENT; SMOKING;

NICOTIANA TABACUM;

EID: 33748420203     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2006.00785.x     Document Type: Review

References (35)

1. Aardema, M. J., & MacGregor, J. T. (2002). Toxicology and genetic toxicology in the new era of "toxicogenomics": Impact of "-omics" technologies. Mutation Research, 499(1), 13-25.
2. Alexandrov, K., Cascorbi, I., Rojas, M., Bouvier, G., Kriek, E., & Bartsch, H. (2002). CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: Comparison with aromatic/hydrophobic adduct formation. Carcinogenesis, 23(12), 1969-1977.
3. Bitton, A., Neuman, M. D., Barnoya, J., & Glantz, S. A. (2005). The p53 tumour suppressor gene and the tobacco industry: Research, debate, and conflict of interest. Lancet, 365(9458), 531-540.
4. Brafman, R. I. (2004). A simplifier for propositional formulas with many binary clauses. IEEE Transactions on Systems, Man, and Cybernetics. Part B Cybernetics, 34(1), 52-59.
5. Campling, B. G., & el-Deiry, W. S. (2003). Clinical implications of p53 mutations in lung cancer. Methods in Molecular Medicine, 75, 53-77.
6. Chang, Y.-R., Amari, S. V., & Kuo, S.-Y. (2004). Computing system failure frequencies and reliability importance measures using OBDD. IEEE Transactions on Computers, 53(1), 54-68
7. Conway, K., Edmiston, S. N., Cui, L., Drouin, S. S., Pang, J., He, M., Tse, C. K., Geradts, J., Dressler, L., Liu, E. T., Millikan, R., & Newman, B. (2002). Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Research, 62(7), 1987-1995.
8. Cox, L. A., Jr. (1985). A new measure of attributable risk for public health applications. Management Science, 31(7), 800-814.
9. Denissenko, M. F., Pao, A., Tang, M., & Pfeifer, G. P. (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science, 274(5286), 430-432.
10. Glazko, G. V., Koonin, E. V., & Rogozin, I. B. (2004). Mutation hotspots in the p53 gene in tumors of different origin: Correlation with evolutionary conservation and signs of positive selection. Biochimica et Biophysica Acta, 1679(2), 95-106.
11. Goldman, R., Enewold, L., Pellizzari, E., Beach, J. B., Bowman, E. D., Krishnan, S. S., & Shields, P. G. (2001). Smoking increases carcinogenic polycyclic aromatic hydrocarbons in human lung tissue. Cancer Research, 61(17), 6367-6371.
12. Greenland, S., & Brumback, B. (2002). An overview of relations among causal modeling methods. International Journal of Epidemiology, 31(5), 1030-1037.
13. Greenland, S., & Robins, J. M. (1988). Conceptual problems in the definition and interpretation of attributable fractions. American Journal of Epidemiology, 128(6), 1185-1197.
14. Gyorffy, E., Anna, L., Gyori, Z., Segesdi, J., Minarovits, J., Soltesz, I., Kostic, S., Csekeo, A., Poirier, M. C., & Schoket, B. (2004). DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: Correlations between tissues and detection by 32P-postlabelling and immunoassay. Carcinogenesis, 25(7),1201-1209.
15. Hazelton, W. D., Clements, M. S., & Moolgavkar, S. H. (2005). Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiology, Biomarkers & Prevention, 14(5), 1171-1181.
16. Hoffmann, K., Heidemann, C., Weikert, C., Schulze, M. B., & Boeing, H. (2005). Estimating the proportion of disease due to classes of sufficient causes. American Journal of Epidemiology.
17. Hofler, M. (2005). Causal inference based on counterfactuals. BMC Medical Research Methodology, 5, 28.
18. Leighton, J. K. (2005). Application of emerging technologies in toxicology and safety assessment: Regulatory perspectives. International Journal of Toxicology, 24(3), 153-155.
19. Li, D., Firozi, P. F., Chang, P., Wang, L. E., Xiong, P., Sturgis, E. M., Eicher, S. A., Spitz, M. R., Hong, W. K., & Wei, Q. (2001a). In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck. International Journal of Cancer, 93(3), 436-440.
20. Li, D., Firozi, P. F., Wang, L. E., Bosken, C. H., Spitz, M. R., Hong, W. K., & Wei, Q. (2001b). Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: A case control analysis. Cancer Research, 61(4), 1445-1450. [Erratum in: Cancer Res 2001a Apr 15;61(8):3531.]
21. Lodovici, M., Akpan, V., Giovannini, L., Migliani, F., & Dolara, P. (1998). Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. Chemico-Biological Interactions, 116(3), 199-212.
22. Martins, J., & Mendes, R. V. (2001). Neural networks and logical reasoning systems: A translation table. International Journal of Neural Systems, 11(2), 179-186.
23. Motykiewicz, G., Faraglia, B., Wang, L. W., Terry, M. B., Senie, R. T., & Santella, R. M. (2002). Removal of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts as a measure of DNA repair capacity in lymphoblastoid cell lines from sisters discordant for breast cancer. Environmental and Molecular Mutagenesis, 40(2), 93-100.
24. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P., & Harris, C. C. (2004). TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Scientific Publications, 157, 247-270.
25. Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N., Hecht, S. S., & Hainaut, P. (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21(48), 7435-7451.
26. Pfeifer, G. P., & Hainaut, P. (2003). On the origin of G → T transversions in lung cancer. Mutation Research, 526(1-2), 39-43.
27. Pott, F., & Heinrich, U. (1990). Relative significance of different hydrocarbons for the carcinogenic potency of emissions from various incomplete combustion processes. IARC Scientific Publications, 104, 288-297.
28. Rodin, S. N., & Rodin, A. S. (2002). On the origin of p53 G:C → T:A transversions in lung cancers. Mutation Research, 508(1-2), 1-19.
29. Rodin, S. N., & Rodin, A. S. (2004). On the excess of G → T transversions in the p53 gene in lung cancer cell lines. Reply to Pfeifer and Hainaut. Mutation Research, 545(1-2), 141-144. [Author reply 145-6; discussion 147.]
30. Rojas, M., Marie, B., Vignaud, J. M., Martinet, N., Siat, J., Grosdidier, G., Cascorbi, I., & Alexandrov, K. (2004). High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: Comparison with lung parenchyma. Cancer Letters, 207(2), 157-163.
31. Rothman, K. J., & Greenland, S. (2005). Causation and causal inference in epidemiology. American Journal of Public Health, 95(Suppl. 1), S144-S150.
32. Shipley, B. (2000). Cause and Correlation in Biology. A User's Guide to Path Analysis, Structural Equations and Causal Inference. Cambridge University Press. Available at http://callisto.si.usherb.ca:8080/bshipley/my%20book.htm.
33. Stellman, S. D., Takezaki, T., Wang, L., Chen, Y., Citron, M. L., Djordjevic, M. V., Harlap, S., Muscat, J. E., Neugut, A. I., Wynder, E. L., Ogawa, H., Tajima, K., & Aoki, K. (2001). Smoking and lung cancer risk in American and Japanese men: An international case-control study. Cancer Epidemiology, Biomarkers & Prevention, 10(11), 1193-1199.
34. Wohlfahrt, J., Andersen, P. K., & Melbye, M. (1999). Multivariate competing risks. Statistics in Medcine, 18(9), 1023-1030.
35. Wreathall, J., & Nemeth, C. (2004). Assessing risk: The role of probabilistic risk assessment (PRA) in patient safety improvement. Quality & Safety in Health Care, 13(3), 206-212.